Clinical Trials
344 trialsNCT06597734 2026-05-20
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06522373 2026-05-15
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT07585734 2026-05-14
Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT06570915 2026-05-13
T-ALL-2024
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Withdrawn
NCT07428486 2026-05-07
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT07498465 2026-05-05
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
Children's Oncology Group
Phase 1 Withdrawn
NCT05660421 2026-04-27
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
NCT04953312 2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT07071909 2026-01-06
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT02315157 2025-10-15
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Phase 1 Withdrawn
NCT04500548 2025-09-10
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05968170 2025-07-14
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
Children's Hospital Los Angeles
Phase NA Withdrawn
NCT06013904 2025-07-04
Difficult PIV Placement in the Pediatric ED
University of Texas at Austin
Phase NA Withdrawn
NCT07046481 2025-07-01
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
Region Skane
Phase NA Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT05248685 2025-06-11
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT06839872 2025-06-05
BOSS
AstraZeneca
Phase 2 Withdrawn
NCT06770257 2025-06-03
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Withdrawn
NCT06572631 2025-05-25
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
Phase 1 Withdrawn
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT05600556 2025-05-15
Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)
Thomas Jefferson University
Phase NA Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT01660347 2025-05-02
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
Thomas Jefferson University
Phase NA Withdrawn
NCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
NCT05595135 2025-04-29
Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study
Thomas Jefferson University
Phase NA Withdrawn
NCT05766514 2025-04-22
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
Phase 2 Withdrawn
NCT06351306 2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2 Withdrawn
NCT06113289 2025-03-12
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04781855 2025-02-28
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04808115 2024-11-26
IIT PH1 KDS-1001 in Patients With CML
Duke University
Phase 1 Withdrawn
NCT06543511 2024-11-22
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT05266950 2024-11-14
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT04523623 2024-10-26
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
Washington University School of Medicine
Phase NA Withdrawn
NCT05288595 2024-10-18
TCR Alpha/Beta and CD19-deplete Haplo-HSCT
University of Colorado, Denver
Phase 2 Withdrawn
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT05823480 2024-09-19
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
Phase 1 Withdrawn
NCT05854966 2024-09-19
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT06586099 2024-09-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT05375253 2024-09-03
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
University of Nebraska
Phase 1 Withdrawn
NCT04996745 2024-08-26
Taking POSNA's OrthoKids to the People
Louisiana State University Health Sciences Center in New Orleans
Phase NA Withdrawn
NCT06007911 2024-08-13
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 1 Withdrawn
NCT05622591 2024-08-07
Pediatric AML
Elucida Oncology
Phase 1 Withdrawn
NCT01239108 2024-08-02
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Astex Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn